IRMD in the 13F filings
Iradimed Corp · CUSIP 46266A109
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 10 Feb 2026
- Managers listing it
- 22
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 3 listed it in both
- Shares listed
- 1,052,599
- combined, among listed positions
- Reported value
- $102m
- combined, at the quarter end
Among the 92 comparable managers: 13 buyers (opened or added shares) and 8 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +33,910.
Managers listing IRMD in Q4 2025
22 of 22 holders
Largest increases and reductions, by shares
Increases
- Fidelity (FMR LLC)existing position · 66,732 shares now+46,274
- Invesco Ltdexisting position · 35,131 shares now+29,010
- Citadel Advisors LLCexisting position · 55,758 shares now+22,031
- Tudor Investment Corpexisting position · 31,177 shares now+21,817
- Susquehanna International Group LLPexisting position · 20,995 shares now+18,145
Reductions
- Millennium Management LLCexisting position · 3,202 shares now-94,982
- Renaissance Technologies LLCexisting position · 456,412 shares now-32,350
- Jane Street Group LLCexisting position · 25,219 shares now-3,765
- Verition Fund Management LLCexisting position · 6,116 shares now-3,512
- Polen Capital Management LLCexisting position · 26,891 shares now-1,568
New positions and exits
New (2)
Exited (1)
- D. E. Shaw & Co.was $730k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2017 | 1 | $171k | n.a. | n.a. |
| Q3 2018 | 1 | $611k | n.a. | n.a. |
| Q4 2018 | 1 | $213k | n.a. | n.a. |
| Q1 2019 | 1 | $244k | n.a. | n.a. |
| Q3 2021 | 1 | $1.1m | n.a. | n.a. |
| Q4 2021 | 1 | $32m | n.a. | n.a. |
| Q1 2022 | 1 | $6.4m | n.a. | n.a. |
| Q2 2022 | 1 | $5.6m | n.a. | n.a. |
| Q3 2022 | 1 | $5.0m | n.a. | n.a. |
| Q4 2022 | 1 | $4.7m | n.a. | n.a. |
| Q1 2023 | 1 | $7.1m | n.a. | n.a. |
| Q2 2023 | 1 | $8.7m | n.a. | n.a. |
| Q3 2023 | 3 | $34m | n.a. | n.a. |
| Q4 2023 | 3 | $36m | 2 | 1 |
| Q1 2024 | 1 | $6.9m | 0 | 1 |
| Q2 2024 | 1 | $6.3m | 0 | 1 |
| Q3 2024 | 1 | $6.9m | 0 | 1 |
| Q4 2024 | 1 | $7.8m | 1 | 0 |
| Q1 2025 | 1 | $8.2m | 1 | 0 |
| Q2 2025 | 2 | $11m | 1 | 1 |
| Q3 2025 | 3 | $47m | 1 | 2 |
| Q4 2025 | 3 | $62m | 13 | 8 |
| Q1 2026 | 4 | $60m | 18 | 6 |
| Q2 2026 | 2 | $38m | 8 | 16 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
IRMD and LLY →IRMD and JNJ →IRMD and VRTX →Choose a stock to compare with IRMD →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own IRMD, latest filings →Back to the 13F Explorer →